glp 1 and chronic kidney disease GLP-1 the kidney: from physiology to pharmacology and outcomes in diabetes ๐ Real Hope for Kidney
Description
Starting doses of Wegovy and Zepbound will cost the Medicare and Medicaid programs $350 a month and decrease in cost over a two-year period
That is where confusion starts for many patients
This episode connects the dots between regulation, access, pricing, and normalization of obesity treatment, and explains why the people laughing today may be asking how they missed it tomorrow
American Journal of Physiology Renal Physiology
Real-World Impact: The real-world impact is undeniable
